CBUS CIBUS INC

Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call

Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2023 financial results on Thursday, March 21, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Title: Cibus, Inc. Fourth Quarter 2023 Results Conference Call

Event Date: Thursday, March 21, 2024

Time: 4:30 p.m. ET

Participant Numbers: (U.S.), (International)

Event Link:

For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday, April 4, 2024 and can be accessed by dialing (U.S.), (International) and entering replay passcode: 13743898.

A live audio webcast of the call, along with accompanying slides, will be available under "News & Events” in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.

About Cibus

Cibus is a leader in Gene Edited Productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus’ focus is productivity traits for the major global crops such as canola, rice, soybean, and wheat. Cibus is a technology leader in high throughput gene editing technology that enables Cibus to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Using its Trait Machine Process, Cibus has developed a pipeline of five productivity traits including important traits for pod shatter reduction, Sclerotinia resistance and weed management. Its initial traits for pod shatter reduction and weed management are developed in collaborations with leading seed companies. Its other pipeline traits including Sclerotinia resistance are in advanced greenhouse and field trial stages.

Cibus Contacts:

Investor Relations

Karen Troeber

858-450-2636

Jeff Sonnek – ICR

Media Relations

Colin Sanford



203-918-4347

 



EN
07/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CIBUS INC

 PRESS RELEASE

Canada Added to a Growing List of Countries Regulating Cibus’ Gene Edi...

Canada Added to a Growing List of Countries Regulating Cibus’ Gene Editing Technologies Similar to Conventional Breeding Cibus Applauds the Canadian Food Inspection Agency’s (CFIA) New Guidelines for Plants Developed Using Gene Editing SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, applauds the Canadian Food Inspection Agency (CFIA), Animal Feed Division’s publication of its updated f...

 PRESS RELEASE

Cibus to Participate in the BMO Global Farm to Market Conference

Cibus to Participate in the BMO Global Farm to Market Conference SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the BMO Global Farm to Market Conference taking place May 15-16, 2024. Presentation detailsDate: Thur...

 PRESS RELEASE

Cibus Reports First Quarter Financial Results and Provides Business Up...

Cibus Reports First Quarter Financial Results and Provides Business Update Important EU Parliament vote on gene editing continues global momentum for the approval of new genomic techniques (NGTs) as similar to conventional breeding Completed single cell regeneration platform for Wheat – with Canola & Rice, Cibus now has its semi-automated crop platform operational for 3 of the top 5 major crops Signed three agreements in Rice including with Loveland Products Inc., a subsidiary of Nutrien Ltd., and Interoc S.A., for Cibus' two proprietary Herbicide Tolerance traits (HT1 and HT3) Continued...

 PRESS RELEASE

Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 an...

Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates...

 PRESS RELEASE

Cibus Reports Fourth Quarter Financial Results and Provides Business U...

Cibus Reports Fourth Quarter Financial Results and Provides Business Update Completed successful transfers of gene edited elite germplasm back to customers for commercialization for each of its three developed productivity traits: Pod Shatter Reduction (PSR) in Canola and Herbicide Tolerance (HT1 and HT3) in Rice Signed collaboration agreements for trait development with multiple major seed companies, including Bayer, Loveland Products (subsidiary of Nutrien Ltd), Nuseed, and Interoc Reported achievement of successful greenhouse results for two different modes of action for Sclerotinia (W...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch